Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing

Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing

News

On April 13, 2016, Kala Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, announced that it closed a $68 million Series C preferred stock financing.

The WilmerHale team representing Kala in this deal included Lia Der Marderosian, Mick Bain and Leora Rodenstein.

Read Kala's press release.